Molecule to Medicine

What Molecule to Medicine does

Molecule to Medicine (MTM) is a privately held biotechnology ecosystem company founded in 2015 by Tom McCarthy (former CEO of Spinifex Pharmaceuticals, acquired by Novartis in 2015) and Kirsty McCarthy. The company operates as a venture creation and scaling platform that co-creates and incubates early-stage biotech companies targeting first-in-class and best-in-class therapeutics across oncology, immunology, cardiometabolic disease, neuroinflammation, and gastrointestinal disease. As of mid-2025, MTM has created six biotech companies (Grey Wolf Therapeutics, Pathios Therapeutics, ThirtyFiveBio, Melio Bio, Lucia Bio, and Curlew Bio), with Grey Wolf having transitioned to a standalone entity after raising over £80M during its incubation.

MTM's core technical offering is a Bioinformatics Platform that combines AI, computational biology, and high-dimensional data analysis to accelerate target identification, biomarker discovery, and patient stratification across portfolio programmes. The platform is supported by dedicated senior scientists in Computational Biology, Translational Informatics, and Informatics, and is applied to preclinical programmes across all six portfolio companies. Operationally, MTM runs three physical "pods" in Oxford (UK, founded 2015), London (UK, May 2024), and Brisbane (Australia, November 2024), with each pod hosting one or more portfolio companies and benefitting from university commercialisation partnerships (notably UniQuest in Brisbane).

The business model combines equity stakes in portfolio companies with integrated support services spanning drug discovery, bioinformatics, project management, commercial operations, finance, IT, HR, and office management. MTM generates returns primarily through equity realisation as portfolio companies mature, secure independent funding, or reach exit events, supplemented by service and milestone-based arrangements. The company is privately held and founder-controlled, with no disclosed external institutional investment; portfolio companies have collectively raised over $200M (Oxford Pod alone, as of April 2024) from investors including Pfizer Ventures, Earlybird, Oxford Science Enterprises, British Patient Capital, Canaan Partners, Andera Partners, Brandon Capital, UniQuest Extension Fund, and Uniseed. MTM does not publicly disclose pricing or financial figures and operates with approximately 30 employees.

Name

Molecule to Medicine

Legal name

M:M Bio Limited

Website

https://moleculetomedicine.com

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

11–50 employees

Short description

Molecule to Medicine (MTM) is a privately held biotech ecosystem company that co-creates and incubates early-stage therapeutics ventures across oncology, immunology, cardiometabolic, and neuroinflammation indications through three global pods (Oxford, London, Brisbane), combining equity ownership with integrated drug discovery, bioinformatics, and operational support services for portfolio founders.

Ownership category

akta.pro rank

Headquarters

HQ city

Milton, Abingdon

HQ country

United Kingdom

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Infrastructure, Technology or R&D, Operations, Marketing or Sales

Revenue model

1. Ecosystem Company Equity: MTM generates revenue through equity stakes in the biotech companies they co-create and scale within their ecosystem. As companies succeed and become independent or get acquired, MTM realizes returns on their investments.
2. Integrated Support Services: MTM provides integrated support services to ecosystem companies including drug discovery, bioinformatics, project management, commercial operations, finance, and personnel services. These are provided to portfolio companies as part of the ecosystem.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Molecule to Medicine (MTM) operates a global biotech ecosystem that co-creates, incubates and scales early-stage biotechnology companies through physical 'pods' in Oxford, London and Brisbane. It provides entrepreneurs with experienced drug discovery teams, an AI-enabled bioinformatics platform, and integrated operational support (project management, finance, IT, HR, commercial) under equity-based arrangements to progress first-in-class and best-in-class therapeutics from idea to clinical development.

Differentiator

Problem solved

Functional benefit

Products and services

• MTM Global Biotech Ecosystem The flagship offering: a global biotech venture creation and incubation ecosystem with physical pods in Oxford, London and Brisbane that co-creates and scales biotech companies in exchange for equity. It bundles experienced drug discovery talent, agile operations, project management and a bioinformatics platform into a single support offering for biotech founders.
• Pathios Therapeutics MTM ecosystem company developing small molecule inhibitors of GPR65 for oncology and immunology indications. Raised a $33M Series A from Canaan Partners and Brandon Capital, plus a $25M Series B, and collaborates with the University of Nottingham on CNS-penetrating GPR65 inhibitors in preclinical brain tumor models.
• ThirtyFiveBio MTM ecosystem company developing a gut epithelial shield and first-in-class small molecule inhibitors of GPR35 for gastrointestinal diseases and cancers. Raised $20M in seed financing to date and was awarded a £495,000 Innovate UK Biomedical Catalyst grant in 2023 for GPR35 inhibitor preclinical research.
• Melio Bio MTM ecosystem company developing GPR75 inverse agonists for cardiometabolic disease, including obesity. Partnered with the University of Aberdeen for GPR75 target expertise and won the 2025 Pioneer Group / Novo Nordisk Golden Ticket providing rent-free lab space and mentorship.
• Lucia Bio

Quantifiable outcome

• Six biotech companies created with successful funding milestones exceeding $200M raised across ecosystem
• +2 more outcomes

Named customers6 records

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature2 records

Partnerships

Seven partnerships are on record, tiered strategic and core.

• Pioneer Group / Novo NordiskstrategicStrategic or Co-development Partner · 1 February 2025Melio Bio won the Pioneer Group/Novo Nordisk Golden Ticket providing rent-free lab space, mentorship from Novo Nordisk drug discovery experts, and investment support.
• UniQuestcoreStrategic or Co-development Partner · 1 November 2024UniQuest is The University of Queensland's commercialisation company. MTM partners with UniQuest to co-create biotech companies leveraging QEDDI's drug discovery capabilities. Partnership has resulted in Lucia Bio and Curlew Bio forming within the Brisbane Pod.
• University of AberdeenstrategicStrategic or Co-development Partner · 1 January 2024Melio Bio established strategic partnership with University of Aberdeen to leverage deep GPR75 target expertise and success in developing potent selective modulators of drug targets including GPCRs.
• University of NottinghamstrategicStrategic or Co-development Partner · 1 September 2023Pathios collaborates with researchers from University of Nottingham for optimization and evaluation of CNS-penetrating GPR65 inhibitors in preclinical brain tumor models.
• ImmunocorestrategicStrategic or Co-development Partner · 1 April 2023Grey Wolf and Immunocore conducted preclinical research collaboration evaluating ERAP1 inhibition combined with Immunocore's MHC Class I directed TCR bispecific ImmTAC therapy. Research demonstrated improved potency of combination therapy.
• RegeneronstrategicStrategic or Co-development Partner · 1 November 2022Grey Wolf entered clinical supply agreement with Regeneron for PD-1 inhibitor Libtayo (cemiplimab) to be used in combination with GRWD5769 in Phase 1/2 clinical trial.
• Sygnature DiscoverycoreStrategic or Co-development Partner · 1 February 2019Pathios and Sygnature formed strategic partnership for integrated drug discovery programs. Sygnature provides industry-leading expertise in GPCR bioscience, medicinal chemistry, computational chemistry, and screening capabilities. Sygnature also received equity as part of the agreement.

Scale indicators9 records

Recent moves11 records

Expansion highlights4 records

Regional players

• Uniseed: Australia's longest-running research commercialisation fund that co-invested in Lucia Bio with MTM. Comparable as an Australian biotech venture investor with similar focus on university spinout creation.
• Brandon Capital: Australian life sciences venture firm backing MTM's Pathios Therapeutics with $13.2M Series A. Highly relevant regional peer given MTM's Brisbane Pod expansion and shared involvement in Australian biotech development.

Others

• Sygnature Discovery: UK-based integrated drug discovery CRO that partnered with Pathios on GPCR-focused programs. Comparable as an enabling service provider within the biotech ecosystem, representing the type of operational partner MTM co-ordinates for its portfolio companies.

Direct peers

• Apollo Therapeutics: UK-based biotech venture creator co-founded by AstraZeneca, GSK, and others, translating academic research into new companies. Comparable to MTM as a UK biotech company-creation platform, with a similar focus on early-stage drug discovery ventures.
• Medicxi: European biotech venture creator that co-founds and builds single-asset or focused-platform biotech companies from academic science, often co-developing with pharma. Highly comparable to MTM's Oxford-based, equity-driven, company-creation model.
• BioGeneration Ventures (BGV): European early-stage biotech venture capital firm focused on company creation from academic and pharma sources. Comparable to MTM in European biotech venture creation, with similar focus on early-stage asset development.
• Atlas Venture: Boston-based biotech venture firm that builds companies from inception around focused scientific ideas, with similar "venture creation" model to MTM. Comparable in the approach of building lean biotech companies around specific scientific assets.

Emerging players

• Bridge Valley Ventures: UK/US life sciences venture studio building companies from academic science, with comparable focus on early-stage biotech creation and active operational involvement. Comparable in approach though typically invests at earlier stages than MTM.

Broad incumbents

• Syncona Investment Trust: UK-listed biotech investment company that founds, builds, and scales life science companies with a similar venture-creation model. Most directly comparable public peer to MTM's "build, incubate, graduate" approach, though Syncona operates at significantly greater scale.
• SV Health Investors: Healthcare and biotech-focused venture firm with deep UK presence that both creates and invests in biotech companies. Overlaps with MTM in biotech venture creation, but operates as a traditional fund manager rather than an integrated incubator platform.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights1 record

Customer concentration

• LinkedInlinkedin.com/company/moleculetomedicine

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Molecule to Medicine